| |
Gilead, Achillion initiate phase I trial evaluating GS 9132 for treatment of hep C
|
| |
| |
Monday, August 22, 2005 14:00 IST
Foster City, CA
Gilead Sciences and Achillion Pharmaceuticals have begun dosing patients in a Phase I study of GS 9132, also known as ACH-806. Gilead and Achillion are investigating GS 9132 for the treatment of hepatitis C.
The Phase I trial is a double-blind, randomized, placebo-controlled dose-escalation study. The goal of the trial is to evaluate the pharmacokinetics, tolerability and safety of single escalating doses of GS 9132 in healthy volunteers. The study will take place in the United States and will enrol approximately 20 subjects.
In November 2004, Gilead and Achillion established an agreement granting Gilead worldwide rights for the research, development and commercialization of certain Achillion compounds for the treatment of hepatitis C.
GS 9132 is a small molecule inhibitor of hepatitis C virus (HCV) replication, which works through a novel mechanism of action involving HCV protease. GS 9132 was discovered by Achillion, and the company completed the initial work necessary to move the compound into clinical development.
|
|
| |
| |
|
|
|
